Searched for
BAYER PHARMA
Quant Small Cap Fund raises stake in Adani Enterprises and 8 others, trims in Aurobindo Pharma and 4 moreQuant Small Cap Fund increased exposure to Adani Enterprises and eight other stocks in May while reducing holdings in Aurobindo Pharma and ...- Bayer bets big on 'self-care' market to deepen India playGlobal pharma major Bayer is significantly expanding its consumer healthcare presence in India, targeting the burgeoning self-care market e...
- Alembic Pharma gets USFDA tentative nod for generic prostate cancer drugAlembic Pharmaceuticals has secured tentative approval from the USFDA for its generic version of Darolutamide tablets, targeting prostate c...
- El Nino impact: Which stocks will burn & which will fire up as market braces for heat waveIndia faces a strong El Niño, threatening below-normal rainfall and impacting agriculture. While rural-linked sectors like two-wheelers and...
- Sun Pharma looks to outshine rival bids with $13 billion Organon offerSun Pharmaceutical is making its biggest move yet with a $13 billion offer for Organon & Co. This ambitious bid aims to transform the India...
- Sun Pharma closes in on Organon buy, gets set for $12 billion binding bidSun Pharmaceutical Industries is nearing a $12 billion acquisition of Organon & Co, marking its most significant overseas expansion. Follow...
- Bayer acquires remaining 25% stake in Bayer Zydus Pharma Pvt Ltd to secure full ownershipBayer Pharmaceuticals Private Limited and Zydus Lifesciences Limited have concluded their joint venture, Bayer Zydus Pharma Private Limited...
- Sun Pharma inks pact with Bayer to sell drug for chronic kidney diseaseSun Pharma has partnered up with Bayer to market Finerenone, a drug for chronic kidney disease, in India. Bayer grants non-exclusive rights...
- Bayer steps up India R&D, clinical trials"Our strategy for India in pharmaceuticals is to continue to make significant investments, we believe that India is a growing market with a...
- Cadila, Bayer extend JV partnership for three years"The spirit of partnership in this joint venture has all been about channelling the core strengths of both Zydus and Bayer for the benefit ...
- Bayer's Aflibercept injection gets DCGI nod for Diabetic Macular Edema indicationDiabetic Macular Edema occurs when high blood sugar levels damage capillaries that leak fluid into the retina, resulting in swelling and bl...
- Bayer Pharmaceuticals committed to India growth; to push for more R&D"Asia Pacific is the fastest growing region for Bayer's pharmaceuticals sales globally. We are very interested and committed to India and a...
- Sun Pharmaceuticals among bidders for Bayer’s dermatology brandsPrivate equity players KKR, Nordic Capital, Bain Capital, Blackstone and Cinven may also be looking at buying the same assets.
- Bayer challenges IPAB’s compulsory licence order to Natco Pharma on cancer drug Nexavar“We introduce the product after years of research and investment, while companies like Natco merely copy and manufacture the product,” said...
- Bayer demands withdrawal of Natco Pharma's compulsory licenceIn March, India allowed Natco Pharma to legally make and sell a low-cost version of cancer drug Nexavar at 3% of the original medicine's pr...
- Cipla breached patent rights by slashing cancer drug price: Bayer PharmaBayer has not given its consent to Cipla to launch its generic Sorafenib & co's decision to cut price "is clear patent infringement," Bayer...
- Piramal acquires Bayer's molecular imaging portfolio"We had said earlier we will change the idea of our pharma business.We will be moving away from branded generics to intellectual property,"...
- Piramal acquires molecular imaging R&D portfolio of BayerPiramal Healthcare today announced its second major acquisition with worldwide rights to the molecular imaging research and development por...
- Zydus Cadila in talks to market Bayer drugsAhmedabad-based drugmaker Zydus Cadila is in talks with Bayer Schering Pharma AG to market the German firm’s products in Indian retail mark...
- Cipla makes cancer drug cheaperCipla has launched a copycat version of German pharma company Bayer’s cancer medicine Nexavar at one-tenth the price.
Load More
